REVIEWS |
|
M.S. Novikova, O.M. Koteshkova, M.B. Antsiferov
Sulodexide: meta-analysis of the treatment of diabetic nephropathy and literature review
|
12-20 |
|
V.I. Petrov, O.V. Shatalova, M.S. Klykova, N.P. Stetsky
The use of sodium-glucose co-transporter type II (SGLT2) inhibitors in patients with chronic heart failure against the background of type 2 diabetes mellitus
|
21-26 |
|
L.S. Aramisova, I.B. Zhurtova, A.M. Gubachikova
Diabetes mellitus and new coronavirus infection: a look into the past, conclusions on prevention and treatment tactics for the future
|
27-31 |
|
N.A. Demidov
Dipeptyl peptidase type 4 inhibitors for modern therapy of type 2 diabetes mellitus
|
32-38 |
|
|
K.Yu. Aleshnikova, M.A. Dzhavakhyan, V.I. Zvereva, V.N. Dul, D.R. Dzhavakhyan
Promising directions for complex pharmacotherapy of thyroid diseases
|
39-45 |
|
Kh.S. Astamirova, A.I. Gatina, Ya.S. Gorbunova, N.A. Demidov, T.S. Ivanenko, M.I. Kolesnikova, O.A. Lapteva, I.V. Morozova, V.A. Parshina, O.Yu. Presnyakova, E.Yu. Smirnova, N.P. Smirnova, M.A. Startseva, Z.A. Khamrazhanov, N.I. Kholmskaya
How to improve the quality of type 2 diabetes mellitus management in routine clinical practice. experience of using a glycemic variability diary
|
46-50 |
|
I.A. Kurnikova
Diabetic neuropathy: pathophysiological mechanisms and metabolic therapy
|
52-57 |
|
N.A. Chernikova, E.I. Degtyareva
Modern possibilities for assessing glycemia in diabetic patients
|
58-64 |
ORIGINAL ARTICLES |
|
N.I. Volkova, I.Yu. Davidenko, Yu.S. Degtyareva, V.V. Avrutskaya, Yu.A. Sorokina, V.N. Kovalenko
Biochemical markers of various subtypes of gestational diabetes
|
65-70 |
|
T.N. Markova, A.A. Anchutina, M.S. Stas, M.M. Medzhidova
Features of compensation of carbohydrate metabolism in patients with type 2 diabetes mellitus hospitalized with coronavirus infection
|
72-82 |
|
I.Yu. Nikulin, A.E. Bagriy, E.S. Mikhailichenko, A.E. Kutya, Ya.A. Sovpel
Tactics of hypoglycemic treatment in patients with pancreatogenic diabetes: a prospective study
|
84-90 |
|
G.A. Ignatenko, A.E. Bagriy, A.V. Prikolota, O.A. Prikolota, E.S. Mikhailichenko, I.A. Golodnikov, O.N. Bagriy
Experience with the use of valsartan/sacubitril in patients with chronic heart failure in combination with type 2 diabetes mellitus and paroxysmal atrial fibrillation
|
91-97 |
|
A.V. Matveev, S.V. Glagolev, D.A. Sychev
Consumption of oral anticoagulants in hospitals of the Russian Federation: analysis of the dynamics of procurement data
|
98-106 |
|
|
E.V. Biryukova
Theory and practice of use of dipeptidyl peptidase-4 inhibitors: focus on evogliptin
|
108-115 |
|
M.B. Antsiferov, O.M. Koteshkova, D.M. Antsiferova, N.A. Demidov
Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes mellitus: how to choose the right solution
|
116-126 |
|
I.B. Zhurtova, A.M. Gubachikova, L.S. Aramisova, H.A. Abdul Moati, L.A. Anaeva
Metabolic effects of metformin in patients with type 2 diabetes mellitus and new coronavirus infection
|
128-131 |
|
O.S. Elsukova
Intensification of glucose-lowering therapy for type 2 diabetes mellitus using insulin degludec: clinical case analysis
|
132-137 |
|
E.Yu. Smirnova
Modern and safe treatment of type 2 diabetes mellitus. Clinical case of the use of gozogliptin in the treatment of a patient with decompensated diabetes mellitus
|
138-141 |
|
S.V. Bulgakova, L.A. Sharonova, Yu.A. Dolgikh, O.V. Kosareva, E.V. Treneva, D.P. Kurmaev
Features of liver damage in patients with thyrotoxicosis: clinical observation of hepatopathy against the background of taking thyreostatics
|
142-148 |
Русский
